Guggenheim on AnaptysBio (ANAB) Spinoff: 'Additional potential upside may be derived from imsidolimab in generalized pustular psoriasis'
Tweet Send to a Friend
Guggenheim analyst Yatin Suneja reiterated a Buy rating and $140.00 price target on AnaptysBio (NASDAQ: ANAB).The analyst comments "Yesterday, after ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
